文献速递白血病造血干细胞移植与细胞治疗

PCR-NGS检测移植前FLT3-ITD突变负荷的临床应用价值

[Clinical application value of detecting the mutation load of the FLT3-ITD gene before allogeneic hematopoietic stem cell transplantation using PCR-NGS technology].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

本研究建立PCR-NGS检测FLT3-ITD突变负荷的方法,回顾性分析65例接受allo-HSCT的AL患者移植前骨髓样本。PCR-NGS灵敏度达10^-6,较qPCR能更准确预测移植后复发和EFS,移植前VAF≥0.1%及PCR-NGS阳性者预后较差。

要点

  • PCR-NGS检测FLT3-ITD灵敏度达10^-6,线性响应范围10^-1~10^-5。
  • 移植前FLT3-ITD VAF≥0.1%者2年复发率更高、EFS更低。
  • qPCR阴性而PCR-NGS阳性者移植后复发风险仍高于双阴性者。

核心结论

  • 成功建立PCR-NGS检测FLT3-ITD突变负荷方法,灵敏度达10^-6。
  • 与传统qPCR相比,allo-HSCT前PCR-NGS检测FLT3-ITD突变负荷能更准确预测移植结局。

研究设计与样本

  • 回顾性研究,建立PCR-NGS检测FLT3-ITD突变负荷的方法学。
  • 检测2021年1月至2024年6月瑞金医院65例伴FLT3-ITD突变AL患者移植前骨髓样本,并与qPCR比较及生存分析。

主要发现

  • 63例移植前形态学缓解患者中,58例qPCR阴性,其中25例PCR-NGS阳性,VAF中位值0.629%(0.004%~26.350%)。
  • 移植前VAF<0.1%组与≥0.1%组的2年累积复发率分别为11.2%和30.6%(HR=3.159,95%CI:0.950~10.510,P=0.048)。
  • 上述两组2年EFS分别为86.2%和64.5%(HR=2.846,95%CI:0.953~8.500,P=0.050)。
  • PCR-NGS/qPCR均阴性、PCR-NGS阳性/qPCR阴性、双阳性组的2年累积复发率分别为12.5%、26.2%和28.6%(HR=2.892,95%CI:1.122~7.451,P=0.032)。
  • 上述三组2年EFS分别为84.4%、73.8%和57.1%(HR=1.784,95%CI:0.880~3.615,P=0.248)。

关键数值与推荐

  • PCR-NGS检测FLT3-ITD灵敏度10^-6,线性响应范围10^-1~10^-5。
  • 移植前FLT3-ITD VAF≥0.1%与更高的2年累积复发率和更低的2年EFS相关。

临床怎么用

  • allo-HSCT前可用PCR-NGS检测FLT3-ITD突变负荷,较qPCR更灵敏地识别低负荷残留病变。
  • 移植后使用FLT3抑制剂是降低复发率和延长总生存期的保护性因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study aimed to develop a methodology for detecting FMS-like tyrosine kinase 3 (FLT3) gene internal tandem duplication (ITD) mutation burden using polymerase chain reaction-next-generation sequencing (PCR-NGS). The prognostic value of FLT3-ITD mutation burden detected with PCR-NGS in patients with acute leukemia (AL) before allogeneic hematopoietic cell transplantation (allo-HSCT) is investigated. Methods: This retrospective study developed a methodology for detecting FLT3-ITD mutational burden in bone marrow samples isolated from 65 patients with AL with FLT3-ITD mutations who received allo-HSCT from January 2021 to June 2024 at Ruijin Hospital. PCR-NGS was used for data analysis, and results were compared with conventional quantitative PCR (qPCR) . Results: The PCR-NGS assay demonstrated robust performance, with a sensitivity of 10(-6). Pretransplant complete remission with FLT3-ITD negativity via qPCR was achieved in 58 patients, comprising 25 with FLT3-ITD positivity in PCR-NGS [median VAF:0.629% (0.004% -26.350% ) ]. The 2-year probability of relapses and event-free survival (EFS) were 11.2% and 86.2% for patients with FLT3-ITD VAF of <0.1% and 30.6% and 64.5% for those having FLT3-ITD VAF of ≥0.1%, respectively (relapse: HR=3.159, 95% CI: 0.950-10.510, P=0.048; EFS: HR=2.846, 95% CI: 0.953-8.500, P=0.050). Two-year probability of relapses and EFS were 12.5% and 84.4% for patients with both negative PCR-NGS and qPCR, 26.2% and 73.8% for those with positive PCR-NGS and negative qPCR, and 28.6% and 57.1% for patients with both positive PCR-NGS and qPCR (relapse: HR=2.892, 95% CI: 1.122-7.451, P=0.0321; EFS: HR=1.784, 95% CI: 0.880-3.615, P=0.248), respectively, before allo-HSCT. Maintenance therapy with FLT3 inhibitors is a protective factor for reduced relapse rate and better overall survival rate after allo-HSCT. Conclusion: A highly sensitive PCR-NGS assay for FLT3-ITD mutational burden has been developed. Compared with qPCR, PCR-NGS demonstrates superior sensitivity and enables more accurate prediction of posttransplant outcomes in patients with AL undergoing allo-HSCT. 目的: 建立基于二代测序技术的聚合酶链反应(PCR-NGS)检测FMS样酪氨酸激酶3(FLT3)基因内部串联重复(ITD)突变的方法学,初步探索PCR-NGS检测急性白血病(AL)异基因造血干细胞移植(allo-HSCT)前FLT3-ITD的临床应用价值。 方法: 建立PCR-NGS检测FLT3-ITD基因突变负荷方法。PCR-NGS法检测2021年1月至2024年6月在上海交通大学医学院附属瑞金医院血液科进行allo-HSCT的65例伴有FLT3-ITD突变AL患者移植前骨髓样本,检测结果与传统定量PCR(qPCR)方法进行比较,并进行生存分析。 结果: 成功建立PCR-NGS检测FLT3-ITD基因突变方法,灵敏度达10(-6),线性响应范围为10(-1)~10(-5)。63例移植前形态学缓解患者中,58例患者qPCR法检测FLT3-ITD基因突变为阴性,其中25例PCR-NGS法检测阳性[变异等位基因频率(VAF)中位值为0.629%(0.004%~ 26.350%)]。移植前FLT3-ITD基因突变VAF<0.1%组和≥ 0.1%组的2年累积复发率分别为11.2%和30.6%(HR=3.159,95%CI:0.950~10.510,P=0.048),2年无事件生存率分别为86.2%和64.5%(HR=2.846,95%CI:0.953~8.500,P=0.050)。PCR-NGS/qPCR均阴性、PCR-NGS阳性/qPCR阴性和PCR-NGS/qPCR均阳性组的2年累积复发率分别为12.5%、26.2%和28.6%(HR=2.892,95%CI:1.122~7.451,P=0.032),2年无事件生存率分别为84.4%、73.8%和57.1%(HR=1.784;95%CI:0.880~3.615,P=0.248)。移植后使用FLT3抑制剂是降低移植后复发率和延长总生存期的保护性因素。 结论: 成功建立PCR-NGS技术检测FLT3-ITD基因突变负荷方法。与传统qPCR检测技术相比,allo-HSCT前PCR-NGS检测FLT3-ITD突变负荷能更准确预测移植结局。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Shao YC, Zhang YX, Sun WL, et al. [Clinical application value of detecting the mutation load of the FLT3-ITD gene before allogeneic hematopoietic stem cell transplantation using PCR-NGS technology]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41486657. doi:10.3760/cma.j.cn121090-20250325-00147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。